Rifaximin as a Modulator of Microbial Translocation and Immune Activation

NCT ID: NCT01466595

Last Updated: 2018-09-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 73 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-09-30
• Study Completion Date: 2012-11-30

Brief Summary

This study is being done to see whether rifaximin, an antibiotic that works in the intestines, can lower the amount of germs in the intestines of HIV infected persons. It is possible that when the amount of these germs is lowered, an HIV-infected person's immune system will become less active and will have a better chance of recovering. Also, the study will evaluate the safety of using rifaximin in HIV-infected subjects.

Detailed Description

A5286 is a randomized, open-label, two-arm, pilot (phase II) study that evaluated whether 4 weeks of treatment with rifaximin, a non-absorbable antibiotic, decreases markers of immune activation and levels of translocated gut microbial products in HIV-1 infected subjects virally suppressed on ART with CD4+ T-cells < 350 cells/mm^3. Rifaximin were admistered to subjects for 3 weeks. Follow-up continued to week 12. The total sample size was 73 subjects. Subjects were randomized at a 2:1 ratio (rifaximin: no study treatment), using permuted blocks, without institutional balancing.

Subjects were seen through week 12 for clinical and laboratory evaluations, including plasma HIV-1 RNA, CD4+ T-cell count, and safety laboratories. Subjects had 2 baseline visits -- at pre-entry and entry. Study visits were scheduled at weeks 2, 4, 8, and 12. CD4+ T-cell counts and HIV-1 RNA were measured at all weeks; measures of activations, gut-homing markers, and soluble biomarkers were also performed at all weeks.

Conditions

HIV-1 Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A: Treatment with rifaximin

Participants were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.

Group Type: EXPERIMENTAL

Rifaximin

Intervention Type: DRUG

Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.

Arm B: No study treatment

No study treatment for 4 weeks

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Rifaximin

Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• HIV-1 infection
• On ART for at least 96 weeks prior to study entry with a regimen that includes three or more antiretroviral medications. (Ritonavir ≤ 400 mg/day will not be considered a separate antiretroviral agent.)
• No plans to change the antiretroviral regimen at least in the next 3 months after study entry.
• CD4+ cell count < 350 cells/mm3 obtained within 120 days prior to study entry at any laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent.
• All previous CD4+ cell counts should be < 350 cells/mm3 for at least 96 weeks prior to study entry while subjects were on ART. (A single CD4+ cell count ≥ 350 cells/mm3 is permitted within 96 weeks prior to study entry while subjects were on ART.)
• Documentation of HIV-1 RNA below the limit of detection (e.g., < 50 copies/mL on Roche Amplicor HIV-1 Monitor assay, < 75 copies/mL on the Versant HIV-1 RNA assay by branched DNA, < 400 copies/mL on a standard Roche Amplicor assay, < 40 copies/mL on the Abbott m2000sp/m2000rt real-time PCR test, < 48 copies/mL on the COBAS AmpliPrep/TAQMAN HIV-1 assay) verified by at least two measurements prior to study entry, one of which must be at least 48 weeks prior to study entry and one measurement that was obtained between 121 days and 48 weeks prior to study entry.
• Screening HIV-1 RNA below the limit of detection obtained within 120 days prior to study entry using a FDA -approved assay (e.g., < 50 copies/mL on Roche Amplicor HIV-1 Monitor assay, < 75 copies/mL on the Versant HIV-1 RNA assay by branched DNA, < 40 copies/mL on the Abbott m2000sp/m2000rt real-time PCR test, < 48 copies/mL on the COBAS AmpliPrep/TAQMAN HIV-1 assay). (The virologic assay must have a lower limit of detection of ≤ 75 copies/mL.)
• All other plasma HIV-1 RNA measurements in the 48 weeks prior to study entry must be below the limit of detection. (A single detectable measurement of ≤ 200 copies/mL is permitted if RNA levels immediately before and after are below the limits of detection for the assay.)
• Certain fasting laboratory values obtained within 45 days prior to entry as indicated in Section 4.1.9 of the protocol.
• Pre-entry peripheral blood mononuclear cell (PBMC) specimen for assay of the primary immune activation endpoint (change in CD8+ T-cells activation (%HLA-DR+CD38+CD8+ T-cells) has been obtained. Sites must receive confirmation from the processing lab via phone, e-mail, or fax, that this specimen has been entered into the ACTG's Laboratory Data Management System (LDMS).
• Female subjects of reproductive potential must have a negative serum or urine β-HCG pregnancy test with a sensitivity of at least 50 mIU/mL performed within 24 hours prior to study entry.
• If participating in sexual activity that could lead to pregnancy, the female subject must agree to use one form of contraceptive as listed in section 4.1.11 of the protocol while receiving protocol-specified treatment and for 4 weeks after stopping the treatment.
• If the female subject is not of reproductive potential, she is eligible without requiring the use of a contraceptive. Self report is acceptable documentation of sterilization, other contraceptive methods, and menopause.
• Ability and willingness of subject or legally authorized representative to provide informed consent.

Exclusion Criteria

• Active diarrhea (3 or more unformed stools per day) within 28 days prior to study entry (except if site investigator or primary care provider attributes diarrhea to antiretroviral or azithromycin use).
• History of or active inflammatory bowel disease.
• History of or active Clostridium difficile colitis.
• History of significant liver disease, defined as having chronic liver disease (including chronic alcoholic liver disease, hepatitis B or C), plus either: a) ascites, b) encephalopathy, or c) a Child-Pugh Score of > 7.
• Receipt of antimicrobial therapy within 30 days prior to study entry. (NOTE: Antimicrobial use for prophylaxis of opportunistic infections, e.g., azithromycin or trimethoprim-sulfamethoxazole, is allowed.)
• Active infection requiring the use of antibiotics within 30 days prior to study entry.
• Known allergy/sensitivity or any hypersensitivity to components of study drug or their formulation (e.g., allergy to rifampin).
• Serious illness requiring systemic treatment and/or hospitalization within 14 days prior to entry.
• Use of any of the following medications for more than 3 consecutive days within the 60 days prior to study entry:

• Immunosuppressives
• Immune modulators
• Antineoplastic agents
• Probiotics
• Anticoagulants
• Vaccinations within 1 week prior to the pre-entry or study entry visits. (NOTE: Subjects are encouraged to get the flu vaccine prior to study pre-entry visit.)
• Participation on any HIV immunotherapy/therapeutic vaccination trials within 6 months prior to study entry.
• Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
• Breastfeeding.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: collaborator

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Allan R. Tenorio, M.D.

Role: STUDY_CHAIR

Rush University Medical Center

Locations

Alabama Therapeutics CRS (5801)

Birmingham, Alabama, United States

UCLA CARE Center CRS (601)

Los Angeles, California, United States

Stanford CRS (501)

Palo Alto, California, United States

Ucsf Aids Crs (801)

San Francisco, California, United States

University of Colorado Hospital CRS (6101)

Aurora, Colorado, United States

Georgetown University CRS (GU CRS) (1008)

Washington D.C., District of Columbia, United States

Univ. of Miami AIDS CRS (901)

Miami, Florida, United States

The Ponce de Leon Center CRS (5802)

Atlanta, Georgia, United States

Northwestern University CRS (2701)

Chicago, Illinois, United States

Rush Univ. Med. Ctr. ACTG CRS (2702)

Chicago, Illinois, United States

IHV Baltimore Treatment CRS (4651)

Baltimore, Maryland, United States

Massachusetts General Hospital ACTG CRS (101)

Boston, Massachusetts, United States

Brigham and Women's Hosp. ACTG CRS (107)

Boston, Massachusetts, United States

Beth Israel Deaconess Med. Ctr., ACTG CRS (103)

Boston, Massachusetts, United States

Washington U CRS (2101)

St Louis, Missouri, United States

New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477)

Newark, New Jersey, United States

Cornell CRS (7804)

New York, New York, United States

NY Univ. HIV/AIDS CRS (401)

New York, New York, United States

HIV Prevention & Treatment CRS (30329)

New York, New York, United States

AIDS Care CRS (1108)

Rochester, New York, United States

Univ. of Rochester ACTG CRS (1101)

Rochester, New York, United States

Unc Aids Crs (3201)

Chapel Hill, North Carolina, United States

Duke Univ. Med. Ctr. Adult CRS (1601)

Durham, North Carolina, United States

Univ. of Cincinnati CRS (2401)

Cincinnati, Ohio, United States

Case CRS (2501)

Cleveland, Ohio, United States

Metro Health CRS (2503)

Cleveland, Ohio, United States

The Ohio State Univ. AIDS CRS (2301)

Columbus, Ohio, United States

Hosp. of the Univ. of Pennsylvania CRS (6201)

Philadelphia, Pennsylvania, United States

Pittsburgh CRS (1001)

Pittsburgh, Pennsylvania, United States

The Miriam Hosp. ACTG CRS (2951)

Providence, Rhode Island, United States

University of Washington AIDS CRS (1401)

Seattle, Washington, United States

Puerto Rico-AIDS CRS (5401)

San Juan, , Puerto Rico

Countries

United States; Puerto Rico

References

Tenorio AR, Chan ES, Bosch RJ, Macatangay BJ, Read SW, Yesmin S, Taiwo B, Margolis DM, Jacobson JM, Landay AL, Wilson CC; A5286 Team. Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. J Infect Dis. 2015 Mar 1;211(5):780-90. doi: 10.1093/infdis/jiu515. Epub 2014 Sep 11.

Reference Type: DERIVED

PMID: 25214516 (View on PubMed)

Other Identifiers

1U01AI068636

Identifier Type: NIH

Identifier Source: secondary_id

View Link

ACTG A5286

Identifier Type: -

Identifier Source: org_study_id